You are here

Article info

Article menu
Download PDFPDF
Extended report
Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?

Authors

  1. Prof. Christopher P Denton, Centre for Rheumatology, Royal Free and University College Medical School, Rowland Hill Street, Hampstead, London, NW3 2PF, UK; c.denton{at}rfc.ucl.ac.uk
View Full Text

Citation

Carulli MT, Handler C, Coghlan JG, et al
Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?
Annals of the Rheumatic Diseases 2008;67:105-109.

Publication history

  • Accepted June 3, 2007
  • First published June 29, 2007.
Online issue publication 
October 25, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

2008 BMJ Publishing Group and European League Against Rheumatism